AUS
NZ
UK
CA
USA
IND
Highlights
- Total revenues for 2024 reached £180.3 million, marking a 1% YoY decline but a 1% increase at constant exchange rates (CER).
- Consumer healthcare revenue dropped by 2% CER, while prescription medicine revenue saw an 8% CER rise.
- The company anticipates that its FY 2024 profit will align with FY 2023, despite market challenges.
Alliance Pharma plc (LSE:APH), a leading international healthcare group, has released its unaudited trading update for the year ending 31 December 2024, reporting stable performance with some fluctuations in its individual product categories. While total revenues experienced a slight decline of 1% year-on-year (YoY), the company saw growth at constant exchange rates (CER), reflecting a resilient underlying business.
Revenue Breakdown: Consumer Healthcare and Prescription Medicine
The company’s consumer healthcare segment faced mixed results, with a 2% decrease in revenue at CER, reaching £130.7 million. The decline was primarily driven by weaker performances from Nizoral (-21% CER) and Amberen (-7% CER), although key products like Kelo-Cote (+6% CER) and MacuShield (+11% CER) performed well. The Hydromol brand also delivered strong growth, increasing by 14% CER.
On the other hand, the prescription medicine segment showed positive momentum, growing by 8% CER to £49.6 million. Notable drivers of growth included Forceval, which surged 20% CER, and Hydromol, which grew 14% CER, benefitting from increased demand in the dermatology segment.
Outlook and Strategy for 2024
Despite market challenges, Alliance Pharma's board is confident that the company’s full-year profit for 2024 will align with the performance achieved in FY 2023. The group remains focused on improving supply chain efficiency and bolstering the performance of key brands to drive future growth.
